ES2638088T3 - Anticuerpo anti-proteína tirosina fosfatasa de tipo receptor humano - Google Patents

Anticuerpo anti-proteína tirosina fosfatasa de tipo receptor humano Download PDF

Info

Publication number
ES2638088T3
ES2638088T3 ES12722557.1T ES12722557T ES2638088T3 ES 2638088 T3 ES2638088 T3 ES 2638088T3 ES 12722557 T ES12722557 T ES 12722557T ES 2638088 T3 ES2638088 T3 ES 2638088T3
Authority
ES
Spain
Prior art keywords
antibody
seq
cell
set forth
ptprs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12722557.1T
Other languages
English (en)
Spanish (es)
Inventor
Tomohide YAMAZAKI
Jing Zhao
Koji Ishida
Yasue SHIBATA
Minkwon Cho
Mayuki ENDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Application granted granted Critical
Publication of ES2638088T3 publication Critical patent/ES2638088T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
ES12722557.1T 2011-04-28 2012-04-27 Anticuerpo anti-proteína tirosina fosfatasa de tipo receptor humano Active ES2638088T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011101752 2011-04-28
JP2011101752 2011-04-28
PCT/JP2012/061795 WO2012148003A1 (en) 2011-04-28 2012-04-27 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY

Publications (1)

Publication Number Publication Date
ES2638088T3 true ES2638088T3 (es) 2017-10-18

Family

ID=46147004

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12722557.1T Active ES2638088T3 (es) 2011-04-28 2012-04-27 Anticuerpo anti-proteína tirosina fosfatasa de tipo receptor humano
ES17174348T Active ES2788183T3 (es) 2011-04-28 2012-04-27 Anticuerpo anti-proteína tirosina fosfatasa de tipo receptor humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17174348T Active ES2788183T3 (es) 2011-04-28 2012-04-27 Anticuerpo anti-proteína tirosina fosfatasa de tipo receptor humana

Country Status (16)

Country Link
US (2) US9803026B2 (enExample)
EP (2) EP2702412B1 (enExample)
JP (2) JP6001557B2 (enExample)
KR (1) KR101873614B1 (enExample)
CN (1) CN103703372B (enExample)
AU (2) AU2012248158C1 (enExample)
CA (1) CA2834243C (enExample)
ES (2) ES2638088T3 (enExample)
HU (2) HUE054211T2 (enExample)
IL (1) IL229127A (enExample)
MX (1) MX352599B (enExample)
PL (2) PL2702412T3 (enExample)
PT (2) PT3232202T (enExample)
RU (2) RU2715642C2 (enExample)
SG (3) SG10201503257WA (enExample)
WO (1) WO2012148003A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009148B1 (en) 2007-07-02 2018-08-22 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
AU2012248158C1 (en) * 2011-04-28 2017-02-02 Sbi Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase sigma antibody
EP3401329A1 (en) 2011-07-15 2018-11-14 OncoMed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
JP6335896B2 (ja) 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ３結合剤およびその使用法
ES2817897T3 (es) 2012-07-23 2021-04-08 La Jolla Inst Allergy & Immunology PTPRS y proteoglicanos en enfermedad autoinmune
US11160873B2 (en) * 2014-02-04 2021-11-02 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
WO2015117199A1 (en) * 2014-02-04 2015-08-13 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
EP3234598B1 (en) * 2014-12-18 2019-11-06 F.Hoffmann-La Roche Ag Assay and method for determining cdc eliciting antibodies
EP3600421A4 (en) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania ANTI-C5A ANTIBODIES AND USES OF THEM
EP3599843A4 (en) * 2017-03-24 2021-01-13 The Regents of the University of California PROTEOGLYCAN IRREGULARITIES IN ABNORMAL FIBROBLASTS AND THERAPIES BASED ON THEM
US11242398B2 (en) 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
CN112770723B (zh) * 2018-07-25 2024-08-02 阿克罗斯生物科学公司 Cldn 18.2特异性单克隆抗体及其使用方法
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members
WO2021067633A2 (en) * 2019-10-04 2021-04-08 Albert Einstein College Of Medicine Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
CA3225321A1 (en) 2021-07-30 2023-02-02 Nunzio Bottini Ptprs in autoimmunity
CN114426582B (zh) * 2022-01-07 2022-11-25 陕西脉元生物科技有限公司 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用
CN116041526B (zh) * 2022-11-14 2023-09-29 华中农业大学 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
EP4676980A2 (en) * 2023-03-03 2026-01-14 Case Western Reserve University Cell adhesion molecule targeted immunotherapies
CN118994384B (zh) * 2024-08-09 2025-09-26 陕西脉元生物科技有限公司 抗Ri的人源化单克隆抗体及其应用和基于其的检测方法
CN119874900B (zh) * 2025-03-06 2025-10-17 吉林大学 一种单克隆抗体及其在制备治疗肿瘤药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173217A1 (en) 1993-10-01 1995-04-13 Joseph Schlessinger Novel receptor-type phosphotyrosine phosphatase-sigma
JP4498136B2 (ja) 2002-08-01 2010-07-07 Ｓｂｉバイオテック株式会社 マウスインターフェロン産生細胞の検出方法
AU2004220156B2 (en) * 2003-03-14 2007-04-19 Taisho Pharmaceutical Co., Ltd. Monoclonal antibody and hybridoma producing the same
EP1732650A4 (en) 2004-03-27 2008-06-11 Univ Arizona COMPOSITION AND METHOD FOR CANCER TREATMENT
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
AU2006297173A1 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
WO2009003274A1 (en) 2007-06-29 2009-01-08 The Hospital For Sick Children Susceptibility gene for inflammatory bowel disease
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
US20120231014A1 (en) * 2009-08-18 2012-09-13 Case Western Reserve University Neural Regeneration
WO2011097327A2 (en) * 2010-02-02 2011-08-11 La Jolla Institute For Allergy & Immunology Compositions and methods of modulating receptor protein tyrosine phosphatases
AU2012248158C1 (en) * 2011-04-28 2017-02-02 Sbi Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase sigma antibody

Also Published As

Publication number Publication date
PT3232202T (pt) 2020-05-22
AU2016262677A1 (en) 2016-12-08
RU2013152816A (ru) 2015-06-10
AU2012248158C1 (en) 2017-02-02
EP3232202A1 (en) 2017-10-18
IL229127A (en) 2017-11-30
MX2013012393A (es) 2014-04-30
US9803026B2 (en) 2017-10-31
KR101873614B1 (ko) 2018-07-02
RU2715642C2 (ru) 2020-03-02
RU2017118262A3 (enExample) 2018-11-02
EP2702412B1 (en) 2017-07-26
US10730955B2 (en) 2020-08-04
PL2702412T3 (pl) 2018-01-31
US20180155446A1 (en) 2018-06-07
BR112013027631A2 (pt) 2022-01-04
ES2788183T3 (es) 2020-10-20
JP2014524733A (ja) 2014-09-25
AU2016262677B2 (en) 2018-08-30
AU2012248158A1 (en) 2014-01-30
JP2017048183A (ja) 2017-03-09
CA2834243A1 (en) 2012-11-01
RU2017118262A (ru) 2018-11-02
PT2702412T (pt) 2017-11-02
SG10202108240VA (en) 2021-09-29
MX352599B (es) 2017-11-30
SG10201503257WA (en) 2015-06-29
EP3232202B1 (en) 2020-02-19
CA2834243C (en) 2019-08-27
EP2702412A1 (en) 2014-03-05
JP6001557B2 (ja) 2016-10-05
PL3232202T3 (pl) 2020-10-05
HUE034752T2 (en) 2018-02-28
HUE054211T2 (hu) 2021-08-30
SG194614A1 (en) 2013-12-30
WO2012148003A1 (en) 2012-11-01
CN103703372B (zh) 2018-01-26
IL229127A0 (en) 2013-12-31
KR20140033024A (ko) 2014-03-17
CN103703372A (zh) 2014-04-02
AU2012248158B2 (en) 2016-09-08
US20140127223A1 (en) 2014-05-08
JP6412072B2 (ja) 2018-10-24

Similar Documents

Publication Publication Date Title
ES2638088T3 (es) Anticuerpo anti-proteína tirosina fosfatasa de tipo receptor humano
KR101585532B1 (ko) 항-ｉｌｔ7 항체
ES2694165T3 (es) Anticuerpo anti-fosfolipasa D4
BR112013027631B1 (pt) Método para a produção de anticorpo monoclonal ou fragmento que inclui uma região de ligação ao antígeno do mesmo, anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, hibridoma, método para a detecção de uma célula dendrítica plasmocitóide, uso de um anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, e método ex vivo para suprimir a atividade de uma célula dendrítica plasmocitóide
WO2022082005A9 (en) Multispecific binding compounds that bind to pd-l1
HK1188797A (en) Anti-ilt7 antibody
HK1124347B (en) Anti-ilt7 antibody
BR112014018539B1 (pt) Método de preparar um hibridoma que produz um anticorpo monoclonal, hibridoma, anticorpo monoclonal ou um fragmento contendo uma região de ligação ao antígeno do mesmo, método de preparar um anticorpo monoclonal, método ex vivo de detectar uma célula dendrítica plasmacitóide, reagente para a detecção de uma célula dendrítica plasmacitóide, método ex vivo de suprimir uma atividade de uma célula dendrítica plasmacitóide e agente para suprimir uma atividade de uma célula dendrítica plasmacitóide